I-Mab Pharma of Shanghai will collaborate with Roche to conduct US clinical trials that combine I-Mab’s TJD5 candidate with Roche’s approved anti-PD-L1 treatment, Tecentriq®. I-Mab’s TJD5 is a proprietary CD73 antibody that is expected to make checkpoint inhibitors more effective. CD73 is an ecto-enzyme expressed on stromal cells and tumors. It converts extracellular adenosine monophosphate (AMP) to adenosine, which contributes to make the tumor micro-environment more immunosuppressive. In January, I-Mab was granted approval to conduct clinical trials of TJD5 in the US.
Source: China Biotoday
